Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 66.25% is in line with its 5-year average of 64.79%, near the high end of its 5-year range (54.31%–70.89%).
0.32% above its 12-month average of 66.04%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 68.00%.
GROSS MARGIN
66.25%
GROSS MARGIN AVG TTM
66.04%
GROSS MARGIN AVG 3Y
67.21%
GROSS MARGIN AVG 5Y
64.79%
GROSS MARGIN AVG 10Y
45.41%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.32%
CURRENT VS 3Y AVG
-1.43%
CURRENT VS 5Y AVG
+2.25%
CURRENT VS 10Y AVG
+45.90%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.44%
median of 787 covered companies
CURRENT VS SECTOR MEDIAN
+63.82%
vs the sector median at left
Market Cap
$486.35M
Gross Margin
74.83%
TTM Avg
73.30%
3Y Avg
73.96%
5Y Avg
75.53%
Market Cap
$495.60M
Gross Margin
0.00%
TTM Avg
-3746.14%
3Y Avg
-1873.07%
5Y Avg
-1248.71%
Market Cap
$475.60M
Gross Margin
52.05%
TTM Avg
54.84%
3Y Avg
54.67%
5Y Avg
54.23%
Market Cap
$472.03M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$510.79M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
-2215.86%
5Y Avg
-1460.58%
Market Cap
$509.56M
Gross Margin
49.79%
TTM Avg
48.93%
3Y Avg
50.95%
5Y Avg
52.39%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $487.98M | 66.25% | 66.04% | 67.21% | 64.79% |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.35M | 74.83% | 73.30% | 73.96% | 75.53% |
| Oculis Holding AG (OCS)vs › | $495.60M | 0.00% | -3746.14% | -1873.07% | -1248.71% |
| Arvinas, Inc. (ARVN)vs › | $477.13M | 96.43% | 99.01% | 99.50% | 99.67% |
| Cerus Corporation (CERS)vs › | $475.60M | 52.05% | 54.84% | 54.67% | 54.23% |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.03M | 0.00% | 0.00% | 0.00% | 0.00% |
| Allogene Therapeutics, Inc. (ALLO)vs › | $510.79M | 0.00% | 50.00% | -2215.86% | -1460.58% |
| Kamada Ltd. (KMDA)vs › | $471.36M | 40.82% | 42.91% | 40.22% | 37.63% |
| 908 Devices Inc. (MASS)vs › | $509.56M | 49.79% | 48.93% | 50.95% | 52.39% |
| Crescent Biopharma, Inc. (CBIO)vs › | $509.02M | 100.00% | 50.00% | 75.00% | 83.33% |
Gross Margin
66.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 68.00% |
| 2026-03-31 | 64.75% |
| 2025-12-31 | 65.66% |
| 2025-09-30 | 66.47% |
| 2025-06-30 | 65.31% |
| 2025-03-31 | 68.09% |
| 2024-12-31 | 63.77% |
| 2024-09-30 | 70.17% |
| 2024-06-30 | 70.35% |
| 2024-03-31 | 68.26% |
| 2023-12-31 | 63.56% |
| 2023-09-30 | 69.15% |
| 2023-06-30 | 70.19% |
| 2023-03-31 | 70.89% |
| 2022-12-31 | 69.37% |
| 2022-09-30 | 60.21% |
| 2022-06-30 | 57.43% |
| 2022-03-31 | 61.05% |
| 2021-12-31 | 54.31% |
| 2021-09-30 | 56.93% |
| 2021-06-30 | 56.69% |
| 2021-03-31 | 59.91% |
| 2020-12-31 | 64.63% |
| 2020-09-30 | 62.64% |
| 2020-06-30 | 53.80% |
| 2020-03-31 | 43.14% |
| 2019-12-31 | 73.75% |
| 2019-09-30 | 71.76% |
| 2019-06-30 | 71.44% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
